XMT™, an eXceptional Monoclonal Technology™ from Cell Signaling Technology (CST), enables the development and production of antibodies with eXceptional Performance (XP™).

This revolutionary and proprietary technology provides us with access to a broad range of antibody-producing B cells unattainable with traditional monoclonal technologies, allowing more comprehensive screening and the identification of XP™ monoclonal antibodies with: